Clinical trials
Recruiting Phase 2 Recurrence trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
112 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 12 |
| 2024 | 24 |
| 2025 | 38 |
| 2026 | 20 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 112 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 4 |
| Fudan University | 3 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Ming-Yuan Chen | 3 |
| The First Affiliated Hospital of Xiamen University | 3 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| First Affiliated Hospital of Zhejiang University | 2 |
| Fondazione Italiana Linfomi - ETS | 2 |
| Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2 |
| Massachusetts General Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 112 |
| Multiple Myeloma | 13 |
| Neoplasm Metastasis | 12 |
| Lymphoma, Large B-Cell, Diffuse | 10 |
| Lymphoma | 7 |
| Neoplasms | 7 |
| Leukemia, Myeloid, Acute | 6 |
| Lymphoma, Non-Hodgkin | 6 |
| Lymphoma, Mantle-Cell | 5 |
| Carcinoma, Hepatocellular | 4 |
Trials
Showing 1 to 25 of 112. Each trial links to its page on Pharma Observatory.
12 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.